Back to the main directory
Company Analysis / Equity
- Morningstar | Organic Growth, Expanding Markets, and Acquisitions Are Key Catalysts for AMG's Fortunes to Improve by Morningstar
- Agnico-Eagle on Track to Achieve 2 Million-Ounce Production Target by 2020 by Morningstar
- Alexion Reports Solid 3Q and Raises Guidance; Shares Undervalued With Maintained $172 FVE by Morningstar
- Berkshire Hathaway Increases Bet on Banks and Other Financial Services Firms in 3Q by Morningstar
- Morningstar | Rewards Expense Continues to Weigh on Amex's Earnings by Morningstar
- Morningstar | Amgen's Cash Flows Look Protected Despite Biosimilars, but Growth Still Looks Difficult to Achieve by Morningstar
- Morningstar | Apple’s 1Q iPhone Headwinds Look Menacing; Longer-Term Outlook Remains Bright Thanks to Services by Morningstar
- AutoZone Starts Fiscal 2019 Nicely; Our Outlook Remains Intact by Morningstar
- Autoliv Set to Capitalize on Increasing Vehicular Safety Content by Morningstar
- Morningstar | AVB Report 12/7/18 by Morningstar
- Morningstar | BASF Issues Profit Warning on Falling MDI and TDI Prices; Trimming FVE to EUR 74. See Updated Analyst Note from 10 Dec 2018 by Morningstar
- Solid End to 2018 for BB&T, We See Much of the Same in 2019 by Morningstar
- Morningstar | Macro and Political Concerns Loom Large for Brazil's Banks by Morningstar
- Macro and Political Concerns Loom Large for Brazil's Banks by Morningstar
- Morningstar | Bank of America Shows True Earnings Power in 2018, We Expect Much of the Same in 2019. See Updated Analyst Note from 16 Jan 2019 by Morningstar
- Bank of America Shows True Earnings Power in 2018, We Expect Much of the Same in 2019 by Morningstar
- Morningstar | BMO Reports Decent 4Q Results; We Expect Growth to Slow Over the Medium Term by Morningstar
- Morningstar | BNY Mellon's Investment Management Under Pressure in 4Q, as Expected; Servicing Fees OK by Morningstar
- BioMarin’s Rare-Disease Portfolio Is Growing, With a Strong Late-Stage Pipeline by Morningstar
- Blackbaud’s Wide Moat Remains Steady Even With Near-Term Lumpiness; Lowering FVE to $87 by Morningstar
- Morningstar | Despite More Volatile Markets, BlackRock's iShares ETF Platform is Generating Solid Organic Growth by Morningstar
- Boston Beer's Top Line Gaining Momentum, but We Expect Volumes to Decelerate Longer Term. by Morningstar
- Morningstar | Celgene Gives Bristol a Pipeline Beyond Opdivo by Morningstar
- Morningstar | Tariffs Weigh on Brown-Forman's Margins but Underlying Growth Solid; Shares Nearing FVE by Morningstar
- Bunge Announces Leadership Transition; Strategic Review Likely To Yield Portfolio Changes by Morningstar